ADC Therapeutics SA presented an update highlighting its progress in the field of antibody-drug conjugates (ADCs). The company reported continued commercialization of ZYNLONTA® for third-line or later diffuse large B-cell lymphoma (DLBCL), with potential expansion into earlier lines of therapy and additional indications, including follicular lymphoma (FL) and marginal zone lymphoma (MZL). ZYNLONTA® demonstrated a 48.3% overall response rate and a 24.8% complete response rate, with a median time to complete response of 1.5 months and a manageable safety profile. The pipeline also includes a PSMA-targeting ADC candidate, currently advancing through IND-enabling activities, featuring a differentiated exatecan-based payload and novel hydrophilic linker. ADC Therapeutics SA continues to seek research collaborations for its next-generation ADC programs. You can access the full presentation through the link below: [Read the full presentation](https://docs.publicnow.com/786692C3F5E45C6C58FD5162CE8A637A05F3E439)